AU2002220266A1 - Methods for the identification and the treatment of cardiovascular disease - Google Patents
Methods for the identification and the treatment of cardiovascular diseaseInfo
- Publication number
- AU2002220266A1 AU2002220266A1 AU2002220266A AU2026602A AU2002220266A1 AU 2002220266 A1 AU2002220266 A1 AU 2002220266A1 AU 2002220266 A AU2002220266 A AU 2002220266A AU 2026602 A AU2026602 A AU 2026602A AU 2002220266 A1 AU2002220266 A1 AU 2002220266A1
- Authority
- AU
- Australia
- Prior art keywords
- identification
- treatment
- methods
- cardiovascular disease
- cardiovascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24818500P | 2000-11-09 | 2000-11-09 | |
| US60/248,185 | 2000-11-09 | ||
| US25741700P | 2000-12-22 | 2000-12-22 | |
| US60/257,417 | 2000-12-22 | ||
| PCT/US2001/047406 WO2002039122A2 (en) | 2000-11-09 | 2001-11-09 | Methods for the identification and the treatment of cardiovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002220266A1 true AU2002220266A1 (en) | 2002-05-21 |
Family
ID=26939172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002220266A Abandoned AU2002220266A1 (en) | 2000-11-09 | 2001-11-09 | Methods for the identification and the treatment of cardiovascular disease |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20030166017A1 (en) |
| AU (1) | AU2002220266A1 (en) |
| WO (1) | WO2002039122A2 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030194703A1 (en) * | 2000-11-13 | 2003-10-16 | Stacey Bolk | Association of thrombospondin polymorphisms with vascular disease |
| JP2004121218A (en) * | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | Method for testing bronchial asthma or chronic obstructive pulmonary disease |
| US7655411B2 (en) * | 2002-08-23 | 2010-02-02 | W2 Holdings, Inc. | Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer |
| EP1522857A1 (en) * | 2003-10-09 | 2005-04-13 | Universiteit Maastricht | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| AU2012244071B2 (en) * | 2003-10-09 | 2014-12-04 | Universiteit Maastricht | Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2 |
| KR20080039878A (en) | 2005-06-24 | 2008-05-07 | 카딜라 핼쓰캐어 리미티드 | Trombospondin-1 Derived Peptides and Methods of Treatment |
| AU2007319576B2 (en) * | 2006-10-06 | 2014-01-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Prevention of tissue ischemia, related methods and compositions |
| EP2192916A4 (en) * | 2007-08-23 | 2012-04-04 | Univ Leland Stanford Junior | MODULATION OF SYNAPTOGENESIS |
| KR101040321B1 (en) | 2007-11-21 | 2011-06-10 | 고려대학교 산학협력단 | Biomarker for Diagnosing Cardiovascular Disease |
| KR101678703B1 (en) * | 2008-10-29 | 2016-11-23 | 비쥐 메디신, 인코포레이티드 | Galectin-3 immunoassay |
| MX2012002371A (en) * | 2009-08-25 | 2012-06-08 | Bg Medicine Inc | Galectin-3 and cardiac resynchronization therapy. |
| CN107703109B (en) * | 2016-08-08 | 2021-01-15 | 华东理工大学 | Two-dimensional molybdenum sulfide polypeptide composite material and application thereof in targeting CD47 cancer marker |
| CN107653312B (en) * | 2017-09-07 | 2021-10-15 | 中国医学科学院阜外医院 | rs7901016 detection system related to blood lipid level and coronary heart disease and related applications |
| WO2020180424A1 (en) | 2019-03-04 | 2020-09-10 | Iocurrents, Inc. | Data compression and communication using machine learning |
| CN111007258A (en) * | 2019-12-20 | 2020-04-14 | 首都儿科研究所附属儿童医院 | Reagent for early diagnosis of Kawasaki disease and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256538A (en) * | 1991-03-08 | 1993-10-26 | Board Of Regents, The University Of Texas System | Detection of early platelet activation and prediagnosis of thrombotic events |
-
2001
- 2001-11-09 WO PCT/US2001/047406 patent/WO2002039122A2/en not_active Ceased
- 2001-11-09 US US10/008,093 patent/US20030166017A1/en not_active Abandoned
- 2001-11-09 AU AU2002220266A patent/AU2002220266A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002039122A3 (en) | 2004-02-26 |
| US20030166017A1 (en) | 2003-09-04 |
| WO2002039122A2 (en) | 2002-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001249881A1 (en) | Method of treating the heart | |
| AU2002338265A1 (en) | Molecules for disease detection and treatment | |
| AU2001275177A1 (en) | Cardiac disease treatment and device | |
| AU2001253565A1 (en) | Cardiac disease treatment and device | |
| AU2001275176A1 (en) | Cardiac disease treatment and device | |
| AU2001281369A1 (en) | Cardiac disease treatment and device | |
| AU2002241520A1 (en) | Blood assessment of injury | |
| AU2002220151A1 (en) | Method and system for the detection of heart disease | |
| AU2002220266A1 (en) | Methods for the identification and the treatment of cardiovascular disease | |
| AU2002237667A1 (en) | Methods for the treatment and prevention of urinary stone disease | |
| AU2001286983A1 (en) | Method of treatment | |
| AU2001260774A1 (en) | Bio-support and preparing method of the same | |
| AU2002329784A1 (en) | Molecules for disease detection and treatment | |
| AU2001245414A1 (en) | Treatment of allergies | |
| HUP0401577A3 (en) | Process for the preparation of 2,4-didezoxyhexoses and 2,4,6-tridezoxyhexoses | |
| AU5565401A (en) | Materials and methods for the treatment of depression | |
| AU2002364890A1 (en) | Molecules for disease detection and treatment | |
| AU2001241709A1 (en) | Molecules for disease detection and treatment | |
| AU2001262177A1 (en) | Method of treatment | |
| AU2002243539A1 (en) | Molecules for disease detection and treatment | |
| AU2002347899A1 (en) | Molecules for disease detection and treatment | |
| AU2002256967A1 (en) | Treating or reducing the risk of cardiovascular disease | |
| AU2001253560A1 (en) | Methods of treatment | |
| AU2002239543A1 (en) | Molecules for disease detection and treatment | |
| AU2002359567A1 (en) | Molecules for disease detection and treatment |